Ritter Daniher Financial Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History

Ritter Daniher Financial Advisory’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-63	Closed	-$1.05K	–	337
2025 Q1	$1.05K	Hold	63	–	–	﹤0.01%	294
2024 Q4	$1.16K	Hold	63	–	–	﹤0.01%	292
2024 Q3	$969	Hold	63	–	–	﹤0.01%	298
2024 Q2	$1.02K	Hold	63	–	–	﹤0.01%	290
2024 Q1	$1.17K	Hold	63	–	–	﹤0.01%	283
2023 Q4	$1.97K	Hold	63	–	–	﹤0.01%	310
2023 Q3	$1.31K	Hold	63	–	–	﹤0.01%	321
2023 Q2	$1.51K	Hold	63	–	–	﹤0.01%	293
2023 Q1	$1.19K	Hold	63	–	–	﹤0.01%	271
2022 Q4	$1K	Hold	63	–	–	﹤0.01%	263
2022 Q3	$1K	Hold	63	–	–	﹤0.01%	230
2022 Q2	$1K	Buy	+63	New	+$1.18K	﹤0.01%	229

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Ritter Daniher Financial Advisory's ACAD Position: Q2 2025 in Review

Ritter Daniher Financial Advisory sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 63 shares — an estimated $1.05K sold.

Ritter Daniher Financial Advisory first reported a position in ACAD in Q2 2022 and held it in 12 quarters. The position peaked at $1.97K in Q4 2023. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

Ritter Daniher Financial Advisory reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Ritter Daniher Financial Advisory sold 63 Acadia Pharmaceuticals shares in Q2 2025, an estimated $1.05K.
Ritter Daniher Financial Advisory first reported a position in Acadia Pharmaceuticals in Q2 2022 and held it in 12 quarters.
Ritter Daniher Financial Advisory's Acadia Pharmaceuticals position peaked at $1.97K in Q4 2023.
311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Ritter Daniher Financial Advisory's 13F filing for Q2 2025, filed 11 Aug 2025.